Approval Package for:

APPLICATION NUMBER:

215239Orig1s000

Trade Name: Agamree, oral suspension

Generic or Proper Name: (vamorolone)

Sponsor: Santhera Pharmaceuticals Ltd.

Approval Date: October 26, 2023

Indication: AGAMREE is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
# CONTENTS

## Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Reviews / Information</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Other Action Letters</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>REMS</td>
<td></td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td>X</td>
</tr>
<tr>
<td>Multidiscipline Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>• Summary Review</td>
<td></td>
</tr>
<tr>
<td>• Clinical</td>
<td></td>
</tr>
<tr>
<td>• Non-Clinical</td>
<td></td>
</tr>
<tr>
<td>• Statistical</td>
<td></td>
</tr>
<tr>
<td>• Clinical Pharmacology</td>
<td></td>
</tr>
<tr>
<td>Product Quality Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Clinical Microbiology / Virology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Other Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td>X</td>
</tr>
</tbody>
</table>
Dear Dr. Fletcher:

Please refer to your new drug application (NDA) received October 26, 2022, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Agamree (vamorolone) oral suspension.

This NDA provides for the use of Agamree (vamorolone) oral suspension for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.\(^1\) Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Instructions for Use) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As.*\(^2\)

The SPL will be accessible via publicly available labeling repositories.

---

\(^1\) [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)

\(^2\) We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm).
CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the carton and container labeling submitted on October 24, 2023, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry SPL Standard for Content of Labeling Technical Qs & As. For administrative purposes, designate this submission “Final Printed Carton and Container Labeling for approved NDA 215239.” Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

Based on the stability data submitted to date, the expiry dating period for Agamree (vamorolone) oral suspension shall be 24 months from the date of manufacture when stored at 20°C to 25°C.

RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER

We also inform you that your request for a rare pediatric disease priority review voucher is denied. This application is not eligible for a rare pediatric priority review voucher because it was not deemed eligible for priority review. See section 529(a)(4)(C) of the FD&C Act.

ADVISORY COMMITTEE

Your application for Agamree was not referred to an FDA advisory committee because the safety profile is acceptable for the intended population, the clinical trial design is acceptable, and the efficacy findings were clear.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable. Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

POSTMARKETING REQUIREMENTS UNDER 505(o)

Section 505(o)(3) of the FDCA authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.
We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to identify an unexpected serious risk of carcinogenicity.

Furthermore, the active postmarket risk identification and analysis system as available under section 505(k)(3) of the FDCA will not be sufficient to assess this serious risk.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following studies:

4515-1 Conduct a 2-year carcinogenicity study of vamorolone in rat.

The timetable you submitted on September 29, 2023, states that you will conduct this study according to the following schedule:

Draft Protocol Submission: 03/2025
Final Protocol Submission: 06/2025
Study Completion: 07/2027
Final Report Submission: 03/2028

4515-2 Conduct a carcinogenicity study of vamorolone in mouse.

The timetable you submitted on September 29, 2023, states that you will conduct this study according to the following schedule:

Draft Protocol Submission: 08/2024
Final Protocol Submission: 11/2024
Study Completion: 05/2025
Final Report Submission: 11/2025

FDA considers the term final to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.3

Finally, we have determined that only a clinical trial (rather than a nonclinical or observational study) will be sufficient to assess a signal of a serious risk of a CYP3A4-mediated drug-drug interaction.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following trial:

---

3 See the guidance for Industry Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (October 2019).
Conduct a trial to evaluate the CYP3A4 induction potential of vamorolone in a dedicated clinical drug-drug interaction study to address the serious risk of altered pharmacokinetics of CYP3A4 substrates when used with vamorolone. The study will be an open-label, fixed-sequence phase 1 study conducted in healthy volunteers (male and female). A specific CYP3A4 substrate (e.g., midazolam) would be administered on Day 1. After a sufficient washout, vamorolone would be administered at the highest dose (6 mg/kg) for sufficient duration to induce CYP3A4 (usually around 10-14 days), followed by the administration of specific CYP3A4 substrate along with vamorolone. Pharmacokinetics of the CYP3A4 substrate would be evaluated before and after vamorolone administration to assess the magnitude of CYP3A4 induction.

The timetable you submitted on October 3, 2023, states that you will conduct this trial according to the following schedule:

- Draft Protocol Submission: 01/2024
- Final Protocol Submission: 06/2024
- Trial Completion: 12/2024
- Final Report Submission: 06/2025

FDA considers the term final to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.4

Submit clinical protocol(s) to your IND 118942 with a cross-reference letter to this NDA. Submit nonclinical and chemistry, manufacturing, and controls protocols and all final report(s) to your NDA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate:

Required Postmarketing Protocol Under 505(o), Required Postmarketing Final Report Under 505(o), Required Postmarketing Correspondence Under 505(o).

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B(a)(1) of the FDCA, as well as 21 CFR 314.81(b)(2)(vii) requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B(a)(1) and 21 CFR 314.81(b)(2)(vii) to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and

---

4 See the guidance for Industry Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (October 2019).

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
21 CFR 314.81(b)(2)(vii). We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

REQUESTED PHARMACOVIGILANCE

We request that you perform postmarketing pharmacovigilance to better characterize the risk for liver toxicity in patients taking Agamree. Please provide biannual reports of events of abnormal liver function tests (i.e., GGT and GLDH) with evidence of liver dysfunction (e.g., hepatitis, drug-induced liver injury). Provide narratives of individual cases as well as a synthesized summary and analysis, including incidence in clinical trial cases, postmarketing cases, and total cases. Include information about whether Agamree was discontinued either temporarily or permanently, and patient outcome including resolution and time to resolution. Also provide information on concomitant medications and other potentially confounding factors, time from the first dose of Agamree, time from the last dose of Agamree, as well as demographics.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.5

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.6 Information and Instructions for completing the form can be found at FDA.gov.7

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

POST APPROVAL FEEDBACK MEETING

New molecular entities qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication

---

5 For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.
6 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
7 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

**COMPENDIAL STANDARDS**

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standards for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP’s website.

If you have any questions, contact Brenda Reggettz, PharmD, Regulatory Health Project Manager, by email at Brenda.Reggettz@fda.hhs.gov or by phone at (240) 402-6220.

Sincerely,

{See appended electronic signature page}

Teresa Buracchio, MD
Director
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Instructions for Use

---

8 [https://www.uspnf.com/](https://www.uspnf.com/)
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TERESA J BURACCHIO
10/26/2023 01:14:23 PM